Logo

American Heart Association

  96
  0


Final ID: MDP1806

Zonal Coating Application System for Left Atrial Appendage Occlusion Devices: A Novel Approach to Reduce Peri-Device Leakage and Device Related Thrombus.

Abstract Body (Do not enter title and authors here): Introduction: Left atrial appendage occlusion (LAAO) is an effective method of stroke prevention in patients with atrial fibrillation (AF). However, peri-device leakage (PDL) and device related thrombus (DRT) are common limitations of LAAO. Notably, PDL is associated with an increased risk of thromboembolic events. In order to minimize DRT, the Watchman FLX Pro is coated with PVDF-HFP. We aim to minimize both DRT and PDL with our novel zonal coating application system (ZCAS). ZCAS integrates a two-part thromboresistant and endothelialization promoting coating onto LAAO devices (Figure 1). In order to determine the optimal coating for the endothelialization promoting zone of ZCAS, we validated coating candidates in an in vitro model of LAAO device endothelialization (Figure 2).

Hypothesis: We hypothesized that polyethylene terephthalate (PET) mesh coated with collagen type IV, fibronectin + VEGF, or poly-L-lysine would improve endothelial cell viability and proliferation.

Methods: Human umbilical vein endothelial cells (HUVEC) were cultured in DMEM/F12 supplemented with ATCC’s Endothelial Cell Growth Kit and antibiotics. For the cell viability and proliferation assay, HUVEC cells were cultured in DMEM/F12 supplemented with 2% FBS, 10 mM L-glutamine, and antibiotics. A 96 well plate with PET inserts was coated with three coating candidates. Each coating was applied in three concentrations ([1x], [10x], and [100x]) with triplicates for each concentration. The coatings included collagen type IV ([1x]: 1 ug/cm2), fibronectin ([1x]: 1 ug/cm2) + VEGF ([1x]: 10 ng/cm2), and poly-L-lysine ([1x]: 4 ug/cm2). An MTS assay was performed at 48 hours after plating to assess cell viability and proliferation.

Results: MTS absorbance relative to the uncoated control (MTS absorbance coated well/MTS absorbance uncoated well) for collagen type IV at [1x], [10x], and [100x] was 0.81, 1.29, and 0.84 respectively (Table 1). Fibronectin + VEGF at [1x], [10x], and [100x] was 1.31, 1.62, and 0.96. Finally, poly-L-lysine at [1x], [10x], and [100x] was 0.69, 0.90, and 0.91 respectively.

Conclusion(s): Among the coating candidates, fibronectin (1 ug/cm2) + VEGF (100 ng/cm2) had the greatest increase in cell viability and proliferation compared to the uncoated PET control. The significance of this finding lies in the potential for ZCAS to improve the endothelial seal between the LAAO device and LAA orifice, which may significantly reduce PDL post-implantation.
  • Houmsse, Mustafa  ( Northeast Ohio Medical University , Rootstown , Ohio , United States )
  • Muskara, Andrew  ( Northeast Ohio Medical University , Rootstown , Ohio , United States )
  • Pasca, Damaris  ( Northeast Ohio Medical University , Rootstown , Ohio , United States )
  • Roy, Arnab  ( Northeast Ohio Medical University , Rootstown , Ohio , United States )
  • Author Disclosures:
    Mustafa Houmsse: DO NOT have relevant financial relationships | Andrew Muskara: DO NOT have relevant financial relationships | Damaris Pasca: No Answer | Arnab Roy: No Answer
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Left Atrial Appendage Occlusion (LAAO): Combinations, Comparisons, Cool Tools & Conflicts

Monday, 11/18/2024 , 12:50PM - 02:15PM

Moderated Digital Poster Session

More abstracts on this topic:
A Systematic Review and Meta-Analysis on the Anesthetic Approaches for Left Atrial Appendage Occlusion: Comparing Conscious Sedation and General Anesthesia

Zaidi Syed Rafay, Ajmal Umna, Rauf Zainab, Maaz Muhammad, Gulzar Sara, Burki Shahid, Nazir Abubakar, Mirza Azka, Hassan Ahmad, Amir Maaz, Jahangir Muhammad Asad, Rasul Minahil, Raza Muhammad, Malik Mohammad

A randomized controlled trial of antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherosclerosis: The ATIS-NVAF trial

Okazaki Shuhei, Uchida Kazutaka, Asakura Koko, Omae Katsuhiro, Yamamoto Haruko, Hirano Teruyuki, Toyoda Kazunori, Iguchi Yasuyuki, Noguchi Teruo, Okada Yasushi, Kitagawa Kazuo, Tanaka Kanta, Sakai Nobuyuki, Yamagami Hiroshi, Yazawa Yukako, Doijiri Ryosuke, Koga Masatoshi, Ihara Masafumi, Yamamoto Shiro, Kamiyama Kenji, Honda Yuko

You have to be authorized to contact abstract author. Please, Login
Not Available